PEIJIA-B (09996.HK) plans to hold a Board of Directors meeting on March 25 to approve the annual performance.

Huitong Network reported on March 13 that PEIJIA-B (09996.HK) announced that the Board of Directors will hold a meeting on March 25, 2025 (Tuesday) to consider and approve the annual performance of the company and its subsidiaries for the year ending December 31, 2024, and its release, as well as to consider the proposal for the payment of a final dividend (if any).

Gelonghui FinanceMar 13 17:06

PEIJIA-B: DATE OF BOARD MEETING

HKEXMar 13 17:05 · Announcements

Hong Kong stock Concept tracking | Deepseek sparks an AI Medical craze, increasing the valuation of the Medical Sector (including Concept stocks).

Frost & Sullivan predicts that by 2033, the Medical AI market in China will grow from 8.8 billion yuan in 2023 to 315.7 billion yuan, with a compound annual growth rate of 43.1%.

Zhitong FinanceMar 7 09:41

The new drug development time is cut in half, diagnoses are more accurate, industry barriers are lowered... AI is transforming the Medical Industry in China.

On February 26, Deutsche Bank Analyst Cyrus Ng released a report stating that the entire Medical Industry in China will benefit from the AI revolution, from drug development and diagnostics to hospital management.

wallstreetcnFeb 27 16:39

The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus

① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.

cls.cnFeb 27 09:37

Hong Kong stocks are moving丨PEIJIA-B rose more than 3% to set a new high for the year, with last year's revenue increasing by approximately 38.3%-42.8% year-on-year.

Gelonghui, February 11 | PEIJIA-B (9996.HK) saw its stock price rise by 3.25% to 4.13 Hong Kong dollars today, reaching a new high for the year. PEIJIA-B announced last night that for the year ending December 31, 2024, the company's revenue is expected to be approximately 0.61 billion to 0.63 billion yuan, representing a year-on-year growth of about 38.3% to 42.8%. The strong revenue growth is mainly attributed to: (i) the continued rapid growth of the group's entire neuro-interventional product line; and (ii) the expansion of the group's market share in China for transcatheter aortic valve replacement ("TAVR"). During the reporting period, due to the increase in surgical penetration.

Gelonghui FinanceFeb 11 16:05